You are here
Clinical Trials: Urological Disease
Discuss
Each Clinical Trial will open in a new browser window or tab.
Condition: Renal Artery Stenosis
Intervention: Device: Low-energy extracorporeal ultrasound shockwave therapy (SWT)
Sponsors: Mayo Clinic; National Heart, Lung, and Blood Institute (NHLBI)
Not yet recruiting
Intervention: Device: Low-energy extracorporeal ultrasound shockwave therapy (SWT)
Sponsors: Mayo Clinic; National Heart, Lung, and Blood Institute (NHLBI)
Not yet recruiting
Condition: Stress Urinary Incontinence
Interventions: Device: Sham Fotona SP Dynamis; Device: Intravaginal Fotona SP Dynamis; Device: Intraurethral Fotona SP Dynamis
Sponsor: Fotona d.o.o.
Recruiting
Interventions: Device: Sham Fotona SP Dynamis; Device: Intravaginal Fotona SP Dynamis; Device: Intraurethral Fotona SP Dynamis
Sponsor: Fotona d.o.o.
Recruiting
Conditions: Urologic Diseases; Male Urogenital Diseases; Penile Diseases; Corpus Callosum Malformation; Corpora Cavernosa; Inflammation; Trauma Injury
Intervention: Biological: Autologous tissue engineered corpora
Sponsors: Wake Forest University Health Sciences; United States Department of Defense
Not yet recruiting
Intervention: Biological: Autologous tissue engineered corpora
Sponsors: Wake Forest University Health Sciences; United States Department of Defense
Not yet recruiting
Condition: Urinary Stress Incontinence
Intervention: Other: Muscle Precursor Cells (MPCs), ATMP
Sponsors: University of Zurich; University Hospital Tuebingen; Salzburger Landeskliniken
Not yet recruiting
Intervention: Other: Muscle Precursor Cells (MPCs), ATMP
Sponsors: University of Zurich; University Hospital Tuebingen; Salzburger Landeskliniken
Not yet recruiting
Conditions: Chronic Kidney Diseases; Diabetes Mellitus; Diabetic Nephropathies
Interventions: Dietary Supplement: Fisetin; Drug: Placebo oral capsule
Sponsor: Mayo Clinic
Recruiting
Interventions: Dietary Supplement: Fisetin; Drug: Placebo oral capsule
Sponsor: Mayo Clinic
Recruiting
Conditions: Mesenchymal Stem Cells; Chronic Kidney Diseases; Renal Interstitial Fibrosis
Interventions: Drug: Treatment group; Drug: Control group
Sponsor: The Affiliated Hospital of Xuzhou Medical University
Recruiting
Interventions: Drug: Treatment group; Drug: Control group
Sponsor: The Affiliated Hospital of Xuzhou Medical University
Recruiting
Condition: Diabetic Nephropathies
Intervention: Biological: Wharton Jelly Mesenchymal stem cells
Sponsors: Sophia Al-Adwan; Jordan University of Science and Technology; An-Najah National University
Not yet recruiting - verified September 2017
Intervention: Biological: Wharton Jelly Mesenchymal stem cells
Sponsors: Sophia Al-Adwan; Jordan University of Science and Technology; An-Najah National University
Not yet recruiting - verified September 2017
Conditions: Urologic Diseases; Male Urogenital Diseases; Urethral Stricture; Urethral Injury
Intervention: Biological: Autologous Engineered Urethral Construct
Sponsors: Wake Forest University Health Sciences; United States Department of Defense
Recruiting - verified August 2017
Intervention: Biological: Autologous Engineered Urethral Construct
Sponsors: Wake Forest University Health Sciences; United States Department of Defense
Recruiting - verified August 2017
Conditions: Renal Failure; End Stage Renal Disease; Hemodialysis; Vascular Access
Interventions: Biological: Human Acellular Vessel (HAV); Procedure: Arteriovenous fistula (AVF)
Sponsors: Humacyte, Inc.; CTI Clinical Trial and Consulting Services; California Institute for Regenerative Medicine (CIRM)
Recruiting
Interventions: Biological: Human Acellular Vessel (HAV); Procedure: Arteriovenous fistula (AVF)
Sponsors: Humacyte, Inc.; CTI Clinical Trial and Consulting Services; California Institute for Regenerative Medicine (CIRM)
Recruiting
Condition: Interstitial Cystitis
Intervention: Biological: Platelet-Rich Plasma
Sponsor: Buddhist Tzu Chi General Hospital
Not yet recruiting - verified April 2017
Intervention: Biological: Platelet-Rich Plasma
Sponsor: Buddhist Tzu Chi General Hospital
Not yet recruiting - verified April 2017
